Spain and Andorra face shortages of menopause hormone therapy drugs

Spain and Andorra are experiencing shortages of medications used for hormone replacement therapy (HRT) to treat menopause symptoms. In Spain, the shortage affects women seeking relief from severe symptoms such as hot flashes, night sweats, and mood changes, as well as those using treatment to support bone and cardiovascular health.

In Andorra, the shortage has been described as serious, impacting various transdermal formulations including Lenzetto, Evopad, Oestraclin, Bijuva, and Estradiol. The situation in Andorra is linked to a global supply crisis and is exacerbated by high demand from both local residents and tourists from neighboring countries.

Experts note that demand for HRT has risen as recent findings suggest that previous concerns regarding cancer and cardiovascular risks may have been overstated. Professionals emphasize that these treatments are vital for maintaining bone mass and managing genitourinary issues, though they are not suitable for all patients, particularly those with specific histories of cancer or liver disease.